Cardiogen 50mg

What is Cardiogen (50mg)?

Cardiogen is a short synthetic tetrapeptide also known as AEDR. It has been studied in laboratory research as a peptide bioregulator, particularly for its interactions with cardiac tissue, cell proliferation, and gene expression regulation in experimental models. Published research focuses on Cardiogen in preclinical and mechanistic contexts, not as a clinically established treatment.

• Chemical Formula: C₁₈H₃₁N₇O₉
• Molecular Weight: 489.48 g/mol
• Sequence: Ala-Glu-Asp-Arg

What are the key features of Cardiogen (50mg)?

Cardiogen (50mg) is typically presented in research catalogs as a peptide material intended for controlled laboratory use. Research around AEDR/Cardiogen focuses on peptide–cell interactions, protein expression, and biological responses in cardiac-related experimental models. Key features include:

• Peptide type: Tetrapeptide (4 amino acids, sequence Ala-Glu-Asp-Arg)
• Classification: Short peptide/peptide bioregulator in research literature
• Research focus: Studied in cardiac tissue biology and cell regulation models
• Format: Supplied as a 50 mg vial (verify exact label details with supplier documentation)
• Quality testing: Purity confirmed by lot-specific COA (HPLC/MS verified); refer to supplier documentation for batch-specific values
• Compliance: For laboratory research use only

How is Cardiogen (50mg) synthesized?

Cardiogen is a synthetic peptide, not a natural protein or peptide extract. Its structure is a defined four-residue sequence (Ala-Glu-Asp-Arg), making it suitable for standardized peptide synthesis and analytical characterization in research workflows. The peptide is typically produced using solid-phase peptide synthesis (SPPS) methods and characterized using HPLC for purity and MS for mass confirmation. While biological studies report experimental outcomes, vendor COAs remain the primary source of lot-specific purity and identity data.

What is Cardiogen (50mg) being studied for? What are its possible benefits?

Cardiogen is being investigated primarily in preclinical research related to cardiac tissue biology, including studies on cell proliferation, cytoskeletal and nuclear matrix protein expression, and apoptosis. Some publications also explore its effects in cell proliferation and apoptosis models outside of strictly cardiac contexts. These findings are experimental and do not constitute established therapeutic outcomes. Potential biological benefits under investigation include:

• Modulation of cellular growth behavior
• Altered protein expression patterns
• Effects on tissue remodeling and apoptosis in research models

These findings are based on research observations and should not be interpreted as proven therapeutic effects or clinical efficacy in humans.

How does Cardiogen (50mg) work in research studies?

In research studies, Cardiogen is thought to influence cellular signaling, gene expression, and protein synthesis pathways that regulate cell states. Khavinson et al. reported that H-Ala-Glu-Asp-Arg-OH enhanced the expression of cytoskeletal proteins (actin, tubulin, vimentin) and nuclear matrix proteins (lamin A, lamin C) by 2–5 times in cultured mouse embryonic fibroblasts, suggesting a role in cell proliferation and apoptosis reduction. Other research suggests that low-molecular-weight peptides, such as Cardiogen, may interact with chromatin/DNA-associated systems and regulate gene expression. These findings are experimental observations and should not be interpreted as definitive clinical effects.

What dosing information exists for Cardiogen (50mg)?

Published dosing information for Cardiogen (AEDR) is limited and varies across studies depending on model type (cell culture vs. animal study), endpoint, and administration route. Some studies report effective concentrations in tissue cultures, such as 0.05 ng/mL in rat models, but these values should be treated as model-specific experimental parameters rather than dosing guidelines for the product. Since there are no established human dosing guidelines for Cardiogen (50mg), the vial size should not be interpreted as a dosing recommendation. Researchers should consult study methods and internal protocols where applicable.

How should Cardiogen (50mg) be stored and handled?

Cardiogen (50mg) should be stored according to the supplier’s instructions. Lyophilized peptides are generally stored at low temperatures (around –20 °C), protected from light and moisture, and shielded from repeated freeze-thaw cycles to maintain integrity. If reconstituted for laboratory use, store Cardiogen at 2–8 °C under sterile handling conditions. It is important to label the vial properly, minimize storage time, and follow sterile handling protocols. Shelf life and stability depend on the formulation, packaging, and supplier validation. Always refer to the supplier’s COA for specific storage guidance.

Where can I read more research about Cardiogen (50mg)?

For Cardiogen (AEDR), useful starting points include PubMed-indexed mechanistic papers and broader reviews on short peptide regulation:

1. Levdik NV, Knyazkin IV. Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats. Bulletin of experimental biology and medicine. 2009;148(3):433-436. doi:https://doi.org/10.1007/s10517-010-0730-9 
2. Cardiogen-82 Side Effects: Common, Severe, Long Term. Drugs.com. Published 2025. Accessed March 2, 2026. https://www.drugs.com/sfx/cardiogen-82-side-effects.html 
3. Levdik NV, Knyazkin IV. Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats. Bulletin of experimental biology and medicine. 2009;148(3):433-436. doi:https://doi.org/10.1007/s10517-010-0730-9 

Compliance Statement

This product is intended for laboratory research use only and is not approved for human or veterinary use.